p.2

Attorney Docket Number O 98393 US

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown bylow.

BY: Katri W9

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

VERHEIJDEN ET AL.

Serial Number: 09/744,170

Group Art Unit: 1644

Filed: April 5, 2001

Examiner: Amy Decloux

For: NOVEL PEPTIDES FOR USE IN IMMUNOTHERAPY OF AUTOIMMUNE

DISEASES

## Response to Restriction Requirement

Assistant Commissioner of Patents Washington, D.C. 20231

March 7, 2003

Sir:

In reply to the Restriction Requirement issued February 11, 2003, Applicants elect for prosecution the claims in Group I, claims 1-4 and 6-11, for prosecution in this application.

As the novelty of claim 12 relies on incubating the peripheral blood mononuclear cells with a peptide according to claim 1, it is believed that claim 12 can be examined without additional searching or consideration, and accordingly this election is made with traverse.

Respectfully submitted,

William M. Blackstone

Attorney for Applicants
Registration Number 29,772

Akzo Nobel Patent Department Intervet Inc 405 State Street P.O. Box 318

Millsboro, DE 19966 Tel: (410) 464-0581 Sec. (302) 933-4027 Fax: (302) 934-4305





p. 1

Telefax Transmittal Cover sheet



Intervet Inc. 405 State Street P.O. Box 318 Millsboro, DE 19966 (302) 934-8051

FAX RECEIMED 7, 2003

MAR 7 2003

**GROUP 1600** 

2...pages including cover sheet.

PERSON TO: COMPANY/DEPT TO: FAX NUMBER:

Examiner Amy Decloux Group Art Unit 1644 703 872 9306

PERSON FROM: COMPANY/DEPT FROM: FAX NUMBER:

William M. Blackstone

Intervet, Millsboro Patent Department 302 934 4305

RE: USSN 09/744,170

Attorney Docket Number O 98393 US

Response to Restriction Requirement of February 11, 2003

Please accept the following response to the Restriction Requirement of February 11, 2003. (1 page)

Cintervet

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN PROPRIETARY INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT THE ADDRESSEE, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, NOTIFY US IMMEDIATELY BY TELEPHONE (COLLECT). THANK YOU.